Paclitaxel-loaded poly(N-vinylpyrrolidone)-b-poly(ε-caprolactone) nanoparticles: Preparation and antitumor activity in vivo

Zhu, Zhenshu; Li, Yuan; Li, Xin; Li, Rutian; Jia, Zhijun; Liu, Baorui; Guo, Wei; Wu, Wei; Jiang, Xiqun

doi:10.1016/j.jconrel.2009.11.002

Cited by 147 publications

(127 citation statements)

References 33 publications

Supporting

Mentioning

118

Contrasting

Order By: Relevance

“…Paclitaxel has also been loaded in poly(N-vinylpyrrolidone)-b-poly(epsilon-caprolactone) (PVPb-PCL) nanoparticles (100 nm) generated by a modified nano-precipitation method, achieving a good drug loading (>25 %), and high encapsulation efficiency (>85 %) [458]. The antitumor efficacy was studied in vitro on different cancer cell lines, showing a sustained drug release profile, similar drug cytotoxicity (once released) compared to Taxol, and no cytotoxicity if they were empty (no drug).…”

Section: Paclitaxel Encapsulationmentioning

confidence: 99%

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Pérez-Herrero

Fernández‐Medarde

2015

European Journal of Pharmaceutics and Biopharmaceutics

1,403

754

View full text Add to dashboard Cite

Cancer is the second worldwide cause of death, exceeded only by cardiovascular diseases. It is characterized by uncontrolled cell proliferation and an absence of cell death that, except for hematological cancers, generates an abnormal cell mass or tumor. This primary tumor grows thanks to new vasculatization and, in time, adquires metastatic potential and spreads to other body sites, which causes metastasis and finally death. Cancer is caused by damage or mutations in the genetic material of the cells due to environmental or inherited factors. While surgery and radiotherapy are the primary treatment used for local and non-metastatic cancers, anti-cancer drugs (chemotherapy, hormone and biological therapies) are the choice currently used in metastasic cancers. Chemotherapy is based on the inhibition of the division of rapidly growing cells, which is a characteristic of the cancerous cells, but unfortunately, it also affects normal cells with fast proliferation rates, like the hair follicles, bone marrow and gastrointestinal tract cells, generating the characteristic side effects of chemotherapy. The indiscriminate destruction of normal cells, the toxicity of conventional chemotherapeutic Código de campo cambiado

show abstract

Section: Paclitaxel Encapsulationmentioning

confidence: 99%

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Pérez-Herrero

Fernández‐Medarde

2015

European Journal of Pharmaceutics and Biopharmaceutics

1,403

754

View full text Add to dashboard Cite

show abstract

“…Nanoparticles (~1 mg/mL) were dispersed in distilled water using sonication prior to particle size and zeta potential determinations. Mean hydrodynamic diameters were calculated based on size distribution by Encapsulation efficiency (Zhu et al, 2010) Loading of AVST in chitosan nanoparticles were determined by extracting 5 mg nanoparticles with 1 mL acetone for 6 h. From this solution 0.2 mL was diluted with phosphate buffer pH 6.8 and analyzed by UV spectrophotometer (Shimadzu UV-1800, Japan) at 264 nm against appropriate blank. Drug loading and encapsulation efficiency were calculated by using equation Eq.…”

Section: Characterization Of Nanoparticlesmentioning

confidence: 99%

Atorvastatin calcium loaded chitosan nanoparticles: in vitro evaluation and in vivo pharmacokinetic studies in rabbits

Ahmed¹,

Konwar²,

Sengupta³

2015

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

In this study, we prepared atorvastatin calcium (AVST) loaded chitosan nanoparticles to improve the oral bioavailability of the drug. Nanoparticles were prepared by solvent evaporation technique and evaluated for its particle size, entrapment efficiency, zeta potential, in vitro release and surface morphology by scanning electron microscopy (SEM). In addition, the pharmacokinetics of AVST from the optimized formulation (FT5) was compared with marketed immediate release formulation (Atorva ® ) in rabbits. Particle size of prepared nanoparticles was ranged between 179.3 ± 7.12 to 256.8 ± 8.24 nm with a low polydispersity index (PI) value. Zeta potential study showed that the particles are stable with positive values between 13.03 ± 0.32 to 46.90 ± 0.49 mV. FT-IR studies confirmed the absence of incompatibility of AVST with excipient used in the formulations. In vitro release study showed that the drug release was sustained for 48 h. Results of pharmacokinetics study showed significant changes in the pharmacokinetic parameter (2.2 fold increase in AUC) of the optimized formulation as compared to marketed formulation (Atorva ® ). Thus, the developed nanoparticles evidenced the improvement of oral bioavailability of AVST in rabbit model. Uniterms:Atorvastatin calcium/oral bioavailability/experimental study. Atorvastatin calcium/in vitro release. Atorvastatin calcium/pharmacokinetics. Nanoparticles/drugs bioavailability.No presente estudo, preparamos nanopartículas de quitosana com atorvastatina cálcica (AVST) para melhorar a biodisponibilidade oral do fármaco. As nanopartículas foram preparadas pela técnica de evaporação de solvente, avaliando-se a granulometria, a eficiência de encapsulamento, o potencial zeta, a liberação in vitro e a morfologia da superfície, por meio da microscopia eletrônica de varredura (MEV). Além disso, a farmacocinética da formulação otimizada de AVST (FT5) foi comparada com a formulação comercial, de liberação imediata, comercializada (Atorva®), em coelhos. O tamanho das das nanopartículas variou na faixa de 179,3 a 256,8 ± 7,12 ± 8,24 nm, com baixo índice polidispersibilidade (PI). O estudo do potencial Zeta mostrou que as partículas são estáveis, com valores positivos entre 13,03 ± 0,32 a 46,90 ± 0,49 mV. Os estudos de FT-IR confirmaram a ausência de incompatibilidade de AVST com o excipiente utilizado nas formulações. O estudo de liberação in vitro mostrou que liberação sustentada do fármaco por 48 horas. Os resultados do estudo farmacocinético mostraram alterações significativas nos parâmetros (aumento de 2,2 vezes na ASC) da formulação otimizada em relação à comercializada (Atorva® ). Assim, o desenvolvimento de nanopartículas evidenciou a melhora da biodisponibilidade oral de AVST em coelhos.Uniterms: Atorvastatina cálcica/biodisponibilidade oral/estudo experimental. Atorvastatina cálcica/ liberação in vitro. Atorvastatina cálcica/farmacocinética. Nanopartículas/biodisponibilidade de fármacos.

show abstract

“…25,35 Tet-NPs were prepared by a nanoprecipitation method as described previously, with minor modification. 14,36 Briefly, a predetermined amount of PVP-b-PCL copolymers and Tet were dissolved in acetone.…”

Section: Formulation Of Nanoparticlesmentioning

confidence: 99%

“…35 Then Tet-NPs were prepared by a nanoprecipitation method. PVP is at the outside of the nanoparticle as a hydrophilic part while PCL is at the center of the nanoparticle as a hydrophobic part.…”

Section: Characterization Of Tet-npsmentioning

confidence: 99%

“…33,34 In our previous studies, PVP modification could lengthen the in vivo circulation time of nanoparticles due to a more effective escape from macrophage systems. 35 Therefore, the drugloaded nanoparticles could be considered a "Trojan horse" designed to deliver anticancer drugs. When the nanoparticles are incubated with cancer cells, they are then transferred into the cells through a process called endocytosis, thereby releasing the loaded drugs directly into the cell interior.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

An efficient Trojan delivery of tetrandrine by poly(N-vinylpyrrolidone)-block-poly(ε-caprolactone) (PVP-b-PCL) nanoparticles shows enhanced apoptotic induction of lung cancer cells and inhibition of its migration and invasion

Xu¹,

Hou²,

Zhang³

et al. 2013

IJN

Self Cite

View full text Add to dashboard Cite

Earlier studies have demonstrated the promising antitumor effect of tetrandrine (Tet) against a series of cancers. However, the poor solubility of Tet limits its application, while its hydrophobicity makes Tet a potential model drug for nanodelivery systems. We report on a simple way of preparing drug-loaded nanoparticles formed by amphiphilic poly(N-vinylpyrrolidone)-block-poly(ε-caprolactone) (PVP-b-PCL) copolymers with Tet as a model drug. The mean diameters of Tet-loaded PVP-b-PCL nanoparticles (Tet-NPs) were between 110 nm and 125 nm with a negative zeta potential slightly below 0 mV. Tet was incorporated into PVP-b-PCL nanoparticles with high loading efficiency. Different feeding ratios showed different influences on sizes, zeta potentials, and the drug loading efficiencies of Tet-NPs. An in vitro release study shows the sustained release pattern of Tet-NPs. It is shown that the uptake of Tet-NPs is mainly mediated by the endocytosis of nanoparticles, which is more efficient than the filtration of free Tet. Further experiments including fluorescence activated cell sorting and Western blotting indicated that this Trojan strategy of delivering Tet in PVP-b-PCL nanoparticles via endocytosis leads to enhanced induction of apoptosis in the non-small cell lung cancer cell A549 line; enhanced apoptosis is achieved by inhibiting the expression of anti-apoptotic Bcl-2 and Bcl-xL proteins. Moreover, Tet-NPs more efficiently inhibit the ability of cell migration and invasion than free Tet by down-regulating matrix metalloproteinases (MMP)-2 and MMP-9, as well as up-regulating tissue inhibitor of MMP-3 (TIMP-3). Therefore, data from this study not only confirms the potential of Tet in treating lung cancer but also offers an effective way of improving the anticancer efficiency of Tet by nanodrug delivery systems.

show abstract

Paclitaxel-loaded poly(N-vinylpyrrolidone)-b-poly(ε-caprolactone) nanoparticles: Preparation and antitumor activity in vivo

Cited by 147 publications

References 33 publications

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Atorvastatin calcium loaded chitosan nanoparticles: in vitro evaluation and in vivo pharmacokinetic studies in rabbits

An efficient Trojan delivery of tetrandrine by poly(N-vinylpyrrolidone)-block-poly(ε-caprolactone) (PVP-b-PCL) nanoparticles shows enhanced apoptotic induction of lung cancer cells and inhibition of its migration and invasion

Contact Info

Product

Resources

About

Paclitaxel-loaded poly(N-vinylpyrrolidone)-b-poly(ε-caprolactone) nanoparticles: Preparation and antitumor activity in vivo

Cited by 147 publications

References 33 publications

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Atorvastatin calcium loaded chitosan nanoparticles: in vitro evaluation and in vivo pharmacokinetic studies in rabbits

An efficient Trojan delivery of tetrandrine by poly(N-vinylpyrrolidone)-block-poly(&epsilon;-caprolactone) (PVP-b-PCL) nanoparticles shows enhanced apoptotic induction of lung cancer cells and inhibition of its migration and invasion

Contact Info

Product

Resources

About

An efficient Trojan delivery of tetrandrine by poly(N-vinylpyrrolidone)-block-poly(ε-caprolactone) (PVP-b-PCL) nanoparticles shows enhanced apoptotic induction of lung cancer cells and inhibition of its migration and invasion